Law360, Philadelphia (February 29, 2016, 3:01 PM EST) -- The U.S. Supreme Court refused Monday to review a Third Circuit decision ordering Girardi Keese Law Firm to give $10 million in settlement proceeds from GlaxoSmithKline LLC to a common benefit fund in centralized product liability suits over the diabetes drug Avandia.
The justices shot down a certiorari petition that Girardi Keese filed in late November arguing that the money the firm won on behalf of state-based clients did not belong in the hands of a steering committee for plaintiffs in the Avandia multidistrict litigation program.
The high court did not comment on the case in issuing its order Monday, and...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!